OBJECTIVES: To estimate the impact on the burden of CKD-T2D from a social perspective in Ecuador with the standard of care (SoC) plus Finerenone, a nonsteroidal, selective antagonist of the mineralocorticoid receptor studied for the management of adults with CKD (eGFR ≥ 25mL/min with albuminuria) and T2D.

METHODS: A social perspective was used to determinate the impact the SoC plus Finerenone, using a Markov model consisting of 5 stages of disease: normoalbuminuria, microalbuminuria, macroalbuminuria, End State Renal Disease and death. The direct and indirect costs and disability-adjusted life year (DALYs) were simulated according to a transition Markov model for a cohort of 1,000 40-year-old patients with type 2 Diabetes (T2D) up to life expectancy 77 years old.

RESULTS: The estimated economic burden of the disease at 2022 prices is approximately $104.239 thousands of dollars for every 1,000 people with T2D with only SoC. When the finerenone technology is including in the microalbuminuria and macroalbuminuria stages for this cohort, the findings are: reduction of 12,5% in direct medical costs (mainly fewer dialysis procedures), lower out-of-pocket expenses in 7,3% and a reduction of DALYs (-0,41 years per person) equivalent to a lower loss of productivity of 2.7%. It is estimated that by including this technology, the economic burden of the disease is $102.716 thousands of dollars for every 1,000 people with T2D.

CONCLUSIONS: The added effect of the inclusion of Finerenone is equivalent to reducing the economic burden of disease of CKD-T2D by 1,5% for the cohort analyzed (-$1.523 thousands of dollars).